|
294 Companies |
|
490 Products |
|
490 Products |
|
198 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...1112131415161718192021...156157» |
- | Enrollment change, Trial withdrawal: Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis (clinicaltrials.gov) - Jul 13, 2017
P3, N=0, Withdrawn, Sponsor: Xiaoli Fan
N=40 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial termination: The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients (clinicaltrials.gov) - Jul 12, 2017
P2, N=8, Terminated, Sponsor: Johns Hopkins University
N=40 --> 0 | Not yet recruiting --> Withdrawn N=20 --> 8 | Active, not recruiting --> Terminated; PI left JHU
- | Betaseron (IFN-?-1b) / Bayer
Phase classification: Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis (clinicaltrials.gov) - Jul 12, 2017
P=N/A, N=68, Completed, Sponsor: Bayer
N=20 --> 8 | Active, not recruiting --> Terminated; PI left JHU Phase classification: P4 --> P=N/A
- prezalumab (AMG 557) / Amgen, AstraZeneca
Trial primary completion date: A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sj (clinicaltrials.gov) - Jul 12, 2017
P2a, N=42, Recruiting, Sponsor: MedImmune LLC
Phase classification: P4 --> P=N/A Trial primary completion date: Jul 2017 --> Feb 2018
- ||||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial completion, Trial primary completion date, Combination therapy, Monotherapy: A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants (clinicaltrials.gov) - Jul 11, 2017
P3, N=227, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jul 2017 --> Feb 2018 Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Sep 2015
- | Trial completion: Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (clinicaltrials.gov) - Jul 11, 2017
P2, N=32, Completed, Sponsor: Jacobus Pharmaceutical
Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Sep 2015 Active, not recruiting --> Completed
- | Trial initiation date, Trial primary completion date, Compliance: Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ? (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=120, Recruiting, Sponsor: University Hospital, Brest
Active, not recruiting --> Completed Initiation date: Jul 2016 --> Oct 2016 | Trial primary completion date: Jun 2018 --> Sep 2018
- | Phase classification: Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon (clinicaltrials.gov) - Jul 11, 2017
P4, N=26, Active, not recruiting, Sponsor: Massachusetts General Hospital
Initiation date: Jul 2016 --> Oct 2016 | Trial primary completion date: Jun 2018 --> Sep 2018 Phase classification: P=N/A --> P4
- || Humira (adalimumab) / AbbVie
Enrollment closed, Real-world evidence, Real-world: ROCKA: Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=100, Active, not recruiting, Sponsor: AbbVie
Phase classification: P=N/A --> P4 Recruiting --> Active, not recruiting
- ||||||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Trial completion, Trial primary completion date, Combination therapy: The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM (clinicaltrials.gov) - Jul 11, 2017
P3, N=170, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Oct 2017 --> Jun 2017
- PEC-Direct (PEC-01) / Vertex
Enrollment open: A Safety and Tolerability Study of VC-02 (clinicaltrials.gov) - Jul 11, 2017
P1, N=15, Recruiting, Sponsor: ViaCyte
Active, not recruiting --> Completed | Trial primary completion date: Oct 2017 --> Jun 2017 Not yet recruiting --> Recruiting
- | Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: IIT12: Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS (clinicaltrials.gov) - Jul 7, 2017
P=N/A, N=500, Recruiting, Sponsor: Rocky Mountain MS Research Group, LLC
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2017 --> Dec 2017
- | Trial completion, Biopsy: Collection of Blood, Bone Marrow, Leukapheresis, and Tissue Biopsy Samples From Patients and Their Family Members for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases Laboratory Research Studies (clinicaltrials.gov) - Jul 6, 2017
P=N/A, N=96, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Apr 2017 --> Dec 2017 Suspended --> Completed
- | Trial completion: Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols (clinicaltrials.gov) - Jul 6, 2017
P=N/A, N=587, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Suspended --> Completed Suspended --> Completed
- | Trial primary completion date: Closed-loop Control of Postprandial Glucose Levels After Meals With Different Macronutrients Content in Adults With Type 1 Diabetes (clinicaltrials.gov) - Jul 6, 2017
P2, N=15, Recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
Suspended --> Completed Trial primary completion date: May 2017 --> Sep 2017
- | Trial primary completion date: Insulin-based Strategies to Prevent Hypoglycemia During Exercise (clinicaltrials.gov) - Jul 6, 2017
P=N/A, N=23, Recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
Trial primary completion date: May 2017 --> Sep 2017 Trial primary completion date: Jun 2017 --> Sep 2017
- | Trial initiation date, Trial primary completion date: Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes (clinicaltrials.gov) - Jul 6, 2017
P2, N=30, Not yet recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
Trial primary completion date: Jun 2017 --> Sep 2017 Initiation date: Dec 2016 --> Jan 2018 | Trial primary completion date: Jun 2017 --> Jul 2018
- | Trial primary completion date: A Study of Flt3-Ligand Levels in Sjögrens Syndrome (clinicaltrials.gov) - Jul 5, 2017
P=N/A, N=50, Recruiting, Sponsor: Göteborg University
Initiation date: Dec 2016 --> Jan 2018 | Trial primary completion date: Jun 2017 --> Jul 2018 Trial primary completion date: Jun 2017 --> Dec 2017
- | Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Trial primary completion date: Etaplus: Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Jul 5, 2017
P=N/A, N=126, Completed, Sponsor: Assistance Publique - H
Trial primary completion date: Jun 2017 --> Dec 2017 Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Feb 2017
- | Trial completion: FreeStyle Libre FGM During Summer Camp for Children With Type 1 Diabetes (clinicaltrials.gov) - Jul 4, 2017
P=N/A, N=45, Completed, Sponsor: University of Ljubljana, Faculty of Medicine
Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Feb 2017 Recruiting --> Completed
- | Kineret (anakinra) / SOBI
Trial termination: Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes (clinicaltrials.gov) - Jul 4, 2017
P2, N=1, Terminated, Sponsor: University of Colorado, Denver
Recruiting --> Completed Completed --> Terminated; funding loss, no data was ever collected
- | ATX-MS-1467 / Apitope
Enrollment change: ATX-MS-1467 in Multiple Sclerosis (clinicaltrials.gov) - Jul 2, 2017
P2, N=37, Completed, Sponsor: Merck KGaA
Completed --> Terminated; funding loss, no data was ever collected N=93 --> 37
- | Trial completion, Enrollment change, Trial primary completion date: Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS) (clinicaltrials.gov) - Jul 2, 2017
P=N/A, N=32, Completed, Sponsor: Kessler Foundation
N=93 --> 37 Recruiting --> Completed | N=48 --> 32 | Trial primary completion date: Nov 2015 --> Apr 2017
- ||||||| Erelzi (etanercept biosimilar) / Novartis
Trial completion: EQUIRA: Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 2, 2017
P3, N=376, Completed, Sponsor: Sandoz
Recruiting --> Completed | N=48 --> 32 | Trial primary completion date: Nov 2015 --> Apr 2017 Active, not recruiting --> Completed
- | Enrollment closed: Mitochondrial Dysfunction and Disease Progression (clinicaltrials.gov) - Jul 2, 2017
P=N/A, N=49, Active, not recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | andecaliximab (GS-5745) / Gilead
Enrollment closed, Enrollment change: RA POC: Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 2, 2017
P2, N=15, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=75 --> 15
- | Trial completion: Study of IGRP-specific T Cell in Peripheral Blood of Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jul 2, 2017
P=N/A, N=30, Completed, Sponsor: First Affiliated Hospital of Zhejiang University
Recruiting --> Active, not recruiting | N=75 --> 15 Recruiting --> Completed
- | Trial completion, MRI: Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=94, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed Recruiting --> Completed
- | Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Jun 30, 2017
P2, N=16, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Cause, Development, and Progression of Stiff-Person Syndrome (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=40, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=400, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
No longer recruiting --> Completed Recruiting --> Completed
- | Trial completion: Specimen Collection for Individuals With Lung Disease Associated With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed Recruiting --> Completed
- | cyclophosphamide / Generic mfg.
Trial completion: Treatment of Autoimmune Thrombocytopenia (AITP) (clinicaltrials.gov) - Jun 30, 2017
P1, N=29, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed Recruiting --> Completed
- | Trial completion: Assessment of Patients With Multiple Sclerosis (MS) (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=1388, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed Recruiting --> Completed
- | Trial primary completion date: Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy (clinicaltrials.gov) - Jun 29, 2017
P=N/A, N=40, Enrolling by invitation, Sponsor: University of Chicago
Recruiting --> Completed Trial primary completion date: Jan 2018 --> Jun 2017
- | Phase classification, Trial primary completion date: A Task-oriented Circuit Training in Multiple Sclerosis (clinicaltrials.gov) - Jun 28, 2017
P=N/A, N=60, Recruiting, Sponsor: University Hospital of Ferrara
Trial primary completion date: Jan 2018 --> Jun 2017 Phase classification: P3 --> P=N/A | Trial primary completion date: Mar 2017 --> Mar 2018
- | Trial primary completion date: DP3: Tissue-Specific Metabolic Reprogramming in Diabetic Complications (clinicaltrials.gov) - Jun 28, 2017
P=N/A, N=40, Recruiting, Sponsor: University of Michigan
Phase classification: P3 --> P=N/A | Trial primary completion date: Mar 2017 --> Mar 2018 Trial primary completion date: May 2017 --> May 2018
- Enrollment change, Trial withdrawal: A Study of a New Type of Insulin in Participants With Type 1 Diabetes on Insulin Injection Therapy (clinicaltrials.gov) - Jun 28, 2017
P1, N=0, Withdrawn, Sponsor: Eli Lilly and Company
Trial primary completion date: May 2017 --> May 2018 N=36 --> 0 | Not yet recruiting --> Withdrawn
- Humalog pen (insulin lispro) / Eli Lilly
Enrollment change, Trial withdrawal: A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps (clinicaltrials.gov) - Jun 28, 2017
P1, N=0, Withdrawn, Sponsor: Eli Lilly and Company
N=36 --> 0 | Not yet recruiting --> Withdrawn N=36 --> 0 | Not yet recruiting --> Withdrawn
- Enrollment open, Enrollment change, Trial initiation date: A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Arthritis (clinicaltrials.gov) - Jun 28, 2017
P1, N=12, Recruiting, Sponsor: Arthrogen
N=36 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting | N=15 --> 12 | Initiation date: Feb 2017 --> Jul 2017
- BMS-986142 / BMS, lulizumab pegol (BMS-931699) / BMS
Enrollment change: Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sj (clinicaltrials.gov) - Jun 27, 2017
P2, N=18, Terminated, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | N=15 --> 12 | Initiation date: Feb 2017 --> Jul 2017 N=80 --> 18
- | hydrocortisone / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, IO biomarker: Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) (clinicaltrials.gov) - Jun 27, 2017
P4, N=89, Completed, Sponsor: University of Roma La Sapienza
N=80 --> 18 Recruiting --> Completed | N=50 --> 89 | Trial primary completion date: Sep 2015 --> Jun 2016
- Trial termination: An Electronic Data Capture Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement (clinicaltrials.gov) - Jun 26, 2017
P4, N=42, Terminated, Sponsor: DePuy International
Recruiting --> Completed | N=50 --> 89 | Trial primary completion date: Sep 2015 --> Jun 2016 Active, not recruiting --> Terminated; Study terminated early for business reasons
- | Trial completion: AERCONN: Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity (clinicaltrials.gov) - Jun 26, 2017
P=N/A, N=68, Completed, Sponsor: Universitätsklinikum Hamburg-Eppendorf
Active, not recruiting --> Terminated; Study terminated early for business reasons Active, not recruiting --> Completed
- ||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Trial primary completion date: An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis (clinicaltrials.gov) - Jun 26, 2017
P=N/A, N=100, Completed, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Jul 2015
- Adcetris (brentuximab vedotin) / Seagen, Takeda
Enrollment change, Trial termination, Trial primary completion date: Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus (clinicaltrials.gov) - Jun 26, 2017
P2, N=20, Terminated, Sponsor: Seattle Genetics, Inc.
Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Jul 2015 N=40 --> 20 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2018 --> Jun 2017; Sponsor decision based on portfolio prioritization
- ||| dimethyl fumarate / Generic mfg.
Trial completion, Claims database: Study of Utilization Patterns of Dimethyl Fumarate in Germany (clinicaltrials.gov) - Jun 26, 2017
P=N/A, N=930, Completed, Sponsor: Biogen
N=40 --> 20 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2018 --> Jun 2017; Sponsor decision based on portfolio prioritization Active, not recruiting --> Completed
- Trial primary completion date, IO biomarker: Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients (clinicaltrials.gov) - Jun 26, 2017
P1/2, N=35, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Trial primary completion date: Nov 2009 --> Mar 2011
- ||| Trial completion: IMAGINE-RA: An MRI-guided Treatment Strategy to Prevent Disease Progression in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 23, 2017
P=N/A, N=200, Completed, Sponsor: Professor of Rheumatology, MD, DMSci, Kim Horslev-Petersen
Trial primary completion date: Nov 2009 --> Mar 2011 Active, not recruiting --> Completed
- | Enrollment open, Trial initiation date, Trial primary completion date: Evaluation of the EarEEG System for Detection of Hypoglycaemia-induced Changes in the EEG in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jun 23, 2017
P=N/A, N=20, Recruiting, Sponsor: Odense University Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Feb 2017 --> Jun 2017 | Trial primary completion date: Jun 2017 --> Jan 2018